{
    "clinical_study": {
        "@rank": "18252", 
        "acronym": "DIALEG", 
        "arm_group": [
            {
                "arm_group_label": "Group A: Intramuscular", 
                "arm_group_type": "Experimental", 
                "description": "Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.\nThe punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
            }, 
            {
                "arm_group_label": "Group B: Intraarterial", 
                "arm_group_type": "Experimental", 
                "description": "Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb."
            }, 
            {
                "arm_group_label": "Group C: Intravenous", 
                "arm_group_type": "Experimental", 
                "description": "Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb."
            }, 
            {
                "arm_group_label": "Group D: Control-standard treatment", 
                "arm_group_type": "Other", 
                "description": "Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the presented clinical trial is to evaluate a hypothesis, that BMAC prepared from\n      bone marrow aspirate and injected intramuscularly into ischemic areas of the lower extremity\n      in patients with diabetes mellitus type II., intraarterially into the defect of the limb or\n      with an intravenous application only, has a greater potential to improve the perfusion in\n      the ischemic limbs than standard treatment of NO-CLI. Another aim of the study is to find\n      out differences among three different therapeutic types of BMAC application, to define their\n      effectiveness and safety and to compare the impact of different means of application to the\n      speed of healing of the limb defects and the improvement of perfusion parameters."
        }, 
        "brief_title": "Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Critical Lower Limb Ischemia", 
            "Type-2 Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Secondary hypothesis assumes, that the intravenous application of BMAC in patients with T2DM\n      older than 30 years of age, with a dose of insulin exceeding 0.7 U/kg/day or 50U/day will\n      result in decreasing the insulin dose in the course of 6-month follow-up and in an\n      improvement of the glycHBA1c levels, improvement of the liver and kidney function, decrease\n      of the cholesterol levels and improvement of the immune response parameters, i.e. parameters\n      of lymphocytar blastic transformation, more than in case of patients with intramuscular or\n      intraarterial application of BMAC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  type 2 diabetes mellitus\n\n          -  diagnosis of critical limb ischemia\n\n          -  non-healing defect on the study limb\n\n          -  ABI value < 50 mmHg or ABI< 0.4\n\n          -  TBI value < 40 mmHg or TBI < 0.4\n\n          -  TcPO2 < 20 mmHg in supine position\n\n          -  no other suitable surgical or re-vascularization procedure\n\n          -  age > 18 years\n\n          -  signed Informed Consent\n\n        Exclusion Criteria:\n\n          -  non-signing of the Informed Consent\n\n          -  anticipated life expectancy < 6 months\n\n          -  history of bone-marrow disease\n\n          -  renal failure or dialysis dependency\n\n          -  known malignant disease\n\n          -  health risks excluding the possibility of general anaesthesia or sedation\n\n          -  life-threatening ischaemic heart disease\n\n          -  vast necrosis of the index limb\n\n          -  active infectious disease, or ATB treatment\n\n          -  treatment with immunosupressives\n\n          -  pregnancy, breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01818310", 
            "org_study_id": "2012-T2DM-CLI", 
            "secondary_id": "2012-001825-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A: Intramuscular", 
                "description": "Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.\nThe punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes.", 
                "intervention_name": "Group A: Intramuscular", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Group B: Intraarterial", 
                "description": "Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.", 
                "intervention_name": "Group B: Intraarterial", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Group C: Intravenous", 
                "description": "Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.", 
                "intervention_name": "Group C: Intravenous", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Group D: Control-standard treatment", 
                "description": "Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment", 
                "intervention_name": "Group D: Surgical endovascular treatment with maximum medicamentous treatment", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ischemia", 
            "diabetes mellitus", 
            "bone marrow aspirate concentrate (BMAC)"
        ], 
        "lastchanged_date": "March 21, 2013", 
        "location": {
            "contact": {
                "email": "angio@vol.cz", 
                "last_name": "Vaclav Prochazka, MD, PhD, MSc", 
                "phone": "+42059737", 
                "phone_ext": "2544"
            }, 
            "contact_backup": {
                "email": "katerina.vitkova@fno.cz", 
                "last_name": "Katerina Vitkova, RNDR.", 
                "phone": "+42059737", 
                "phone_ext": "2052"
            }, 
            "facility": {
                "address": {
                    "city": "Ostrava", 
                    "country": "Czech Republic", 
                    "zip": "708 52"
                }, 
                "name": "University Hospital Ostrava"
            }, 
            "investigator": [
                {
                    "last_name": "Frantisek Jaluvka, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jaromir Gumulec, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)", 
        "other_outcome": [
            {
                "description": "The immune response of study subjects will be monitored following the transplantation of stem cells, together with the periphery lymphocyte function (T-cells, B-cells, NK-cells).\nImmune response parameters, (i.e. parameters of lymphocytar blastic transformation)", 
                "measure": "Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "The following laboratory parameters throughout the clinical trial:\nliver and kidney function\nlipid spectra", 
                "measure": "Metabolic response", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "The following parameters will be monitored in the study subjects:\nglycHBA1c levels\nC-peptide", 
                "measure": "Blood glucose and pancreatic function response", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "overall_contact": {
            "email": "angio@vol.cz", 
            "last_name": "Vaclav Prochazka, MC, PhD, MSc", 
            "phone": "+42059737", 
            "phone_ext": "2544"
        }, 
        "overall_contact_backup": {
            "email": "katerina.vitkova@fno.cz", 
            "last_name": "Katerina Vitkova, RNDr", 
            "phone": "+42059737", 
            "phone_ext": "2052"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Ostrava", 
            "last_name": "Vaclav Prochazka, MD, PhD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Czech Republic: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The data for Primary outcome will be collected throughout the first 18 months of the study. The assessed parameters will include amputation-free survival in order to verify the safety and efficacy of the treatment.", 
            "measure": "Amputation-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "reference": [
            {
                "PMID": "10777239", 
                "citation": "Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999 Jun;12(2):123-37. Review."
            }, 
            {
                "PMID": "15714369", 
                "citation": "Clair DG, Dayal R, Faries PL, Bernheim J, Nowygrod R, Lantis JC 2nd, Beavers FP, Kent KC. Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia. Ann Vasc Surg. 2005 Jan;19(1):63-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01818310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.\nIncrease of the monitored parameters of the tissue perfusion measured with LDP-Periflux 5000 (Perimed), i.e. increase of the ABI - ankle-brachial index, TP - toe pressure, TBI- Toe Brachial index and TcpO2- transcutaneous oxygen pressure.\nDecrease of the SPP perfusion parameter - skin perfusion pressure reflecting an inflammatory activity of the affected limb.", 
                "measure": "Tissue perfusion parameters", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.\n- Improvement of the Rutherford scale of CLI", 
                "measure": "Clinical outcome classification", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.\n- Increase of the number and quality of newly created vessels measured according to digital subtraction angiography (DSA) or MR-angiography (in allergic patients)", 
                "measure": "Functional angiogenesis imaging outcome", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "description": "The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.\nMeasurable decrease of pain measured on the scale and QOL questionnaire (RAND-36).\nHealing of the defect or gangrene (size and state of the wound)", 
                "measure": "Quality of life outcome", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "source": "University Hospital Ostrava", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ministry of Health, Czech Republic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Regional Council of the Moravian-Silesian region, KU MSK", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital Ostrava", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}